Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02935400 · ClinicalTrials.gov registry record
Acute Porphyria Biomarkers for Disease Activity
A clinical trial of Acute Intermittent Porphyria and Hereditary Coproporphyria, sponsored by The University of Texas Medical Branch, Galveston.
- Active
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT02935400 is a study of Acute Intermittent Porphyria and Hereditary Coproporphyria that is active but no longer recruiting, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02935400, a study of Acute Intermittent Porphyria and Hereditary Coproporphyria, is active but no longer recruiting, sponsored by The University of Texas Medical Branch, Galveston.
- ACTIVE NOT RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The long term objective of the research is to identify new biomarkers of disease activity in the human acute porphyrias. This pilot study is intended to provide pilot and feasibility data needed to plan larger and more definitive future studies.
Conditions Studied
Interventions
- DRUG Hemin
Study Locations (1)
Texas
- University of Texas Medical Branch - Galveston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-04-28 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02935400
The ClinicalTrials.gov registry entry for NCT02935400 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Acute Intermittent Porphyria appearing as the primary indexed condition, and to 1 intervention - of which Hemin is the first listed.
NCT02935400 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02935400 about?
NCT02935400 is a clinical study titled "Acute Porphyria Biomarkers for Disease Activity". The long term objective of the research is to identify new biomarkers of disease activity in the human acute porphyrias. This pilot study is intended to provide pilot and feasibility data needed to plan larger and more definitive future studies.
What is the current status of trial NCT02935400?
This trial is currently active not recruiting. The enrollment target is 50 participants. The study started on 2014-04-28. Estimated completion is 2026-12-31.
What conditions does trial NCT02935400 study?
This clinical trial studies the following conditions: Acute Intermittent Porphyria, Hereditary Coproporphyria, Variegate Porphyria.
What interventions are being tested in trial NCT02935400?
The interventions under investigation include: Hemin (DRUG).
Who is sponsoring clinical trial NCT02935400?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02935400 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Intermittent Porphyria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.